Here's What We Expect From AbbVie's Immunology Segment in Q4

Key Takeaways AbbVie's immunology segment, led by Skyrizi and Rinvoq, is expected to anchor Q4 and full-year 2025 results.Model estimates project Q4 sales of $4.87B for Skyrizi and $2.33B for Rinvoq on strong IBD demand.AbbVie faces rising competition, but new launches in UC and GCA are expected to support immunology momentum.AbbVie (ABBV) generates a substantial portion of its revenues from its immunology franchise, driven by the encouraging uptake of its two blockbuster drugs — Skyrizi and Rinvoq. The rob ...